Brief: Dualitybio's Next-Generation Her3 Adc Db-1310 Granted FDA Fast Track Designation
22/07/2025 11:22
July 22 (Reuters) - Duality Biotherapeutics Inc 9606.HK: DUALITYBIO'S NEXT-GENERATION HER3 ADC DB-1310 GRANTED FDA FAST TRACK DESIGNATION Source text: ID:nPnb0MTzpa Further company coverage: 9606.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Duality Biotherapeutics
See all newsDuality Biotherapeutics rises most in near six weeks on Roche's Genentech tie-up
Brief: Duality Biotherapeutics Says Global Research And Development Collaboration And License Agreement With Genentech
Brief: Duality Biotherapeutics Obtains Acceptance From Shanghai Securities Regulatory Bureau For Counselling On Proposed RMB Share Listing
Brief: Duality Biotherapeutics Announces Share Repurchase Plan Of Up To $40 Million
Brief: Duality Biotherapeutics Approved Proposed RMB Share Issue On Sci-Tech Board